



Miltenyi Biotec

Automated enrichment of human CD34⁺ cells

CliniMACS Prodigy® HSC Enrichment System

Application

Automated magnetic enrichment process for human CD34⁺ cells from mobilized leukapheresis products, e.g., as starting material for subsequent engineering of hematopoietic stem cells (HSCs).

This application sheet gives an overview on the process specifications and the required materials, illustrates the instrument setup and summarizes the process workflow. It also provides key performance data for the separation process.

Specifications

Process name:	HSC Enrichment
Process capacity:	Scalable process
Normal scale application:	
Target cells:	Up to 0.6×10^9 CD34 ⁺ cells
Total cells:	Up to 60×10^9 total white blood cells (WBC)
Large scale application:	
Target cells:	Up to 1.2×10^9 CD34 ⁺ cells
Total cells:	Up to 120×10^9 total white blood cells (WBC)
Sample volume:	50–600 mL
Elution volume:	Approx. 80 mL
Process time:	Approx. 3–5.5 hours*

*Excludes device setup and optional in-process storage

Materials required

CliniMACS® Materials	Amount required	
	normal scale	large scale
CliniMACS Prodigy® Instrument	1 piece	1 piece
CliniMACS CD34 Reagent	1 vial	2 vials
CliniMACS Prodigy TS 320	1 set	1 set
CliniMACS PBS/EDTA Buffer (2×3 L)	6 L	9 L

Additional material

Transfer Set Coupler/Coupler

Material & equipment

Human serum albumin (HSA), pharmaceutical grade, to be added to the CliniMACS PBS/EDTA Buffer and to the elution solution to a final concentration of 1.0% (w/v)

Elution solution (500 mL, e.g., sodium chloride solution, for infusion), preferably in bag

Transfer Bag(s) 600 mL (optional)

5% IgG solution (10 mL)

Appropriate Luer Lock syringes (10 mL, 30 mL, and 50 mL) and hypodermic 20 gauge needles


Uninterruptable power supply unit (optional)

Sterile docking device


Cell counter

Flow cytometer

Process overview for HSC Enrichment workflow



CliniMACS Prodigy® TS 320 setup



Performance data

Data from 27 mobilized apheresis products are shown in Table 1. The starting cell products were approximately 24 hours old at the start of the enrichment process. Twelve of these products were processed immediately, while fifteen underwent additional in-process storage for up to 16 hours.

This additional storage time did not affect any of the performance criteria, except for CD34⁺ cell yield. The mean yield of CD34⁺ cells was 65.83% without the additional storage time and 52.22% with the additional storage time.

N=27	Starting material			Final cell product				
	Total WBC	CD34 ⁺ cells		CD34 ⁺ cells				CD3 ⁺ cells
	(%)	(%)	Total	Purity (%)	Total	Viability (%)	Yield (%)	Depletion (log)
Mean	4.26×10 ¹⁰	1.09	4.46×10 ⁸	90.66	2.63×10 ⁸	99.80	65.83	4.71
SD	2.14×10 ¹⁰	0.32	2.29×10 ⁸	4.14	1.53×10 ⁸	0.20	6.26	0.26

Table 1: Internal data on the efficiency of CD34⁺ cell enrichment using the HSC Enrichment System.



Miltenyi Biotec B.V. & Co. KG | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macsde@miltenyi.com | www.miltenyibiotec.com

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured, and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA-approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or FDA approval. This publication is for general informational purposes only. While all reasonable care has been taken in the preparation of this publication, Miltenyi Biotec assumes no responsibility for damages or other liabilities due to the accuracy, completeness, or currency of the information herein provided. Changes are periodically made to the information herein; these changes will be incorporated in new editions of the publication. Miltenyi Biotec may make improvements and/or changes in the product(s) and/or the process(es) described in this publication at any time without notice.

CliniMACS, CliniMACS Prodigy, MACS, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2024 Miltenyi Biotec and/or its affiliates. All rights reserved